UBS Group’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $231M | Buy |
15,957,913
+10,064,625
| +171% | +$144M | 0.03% | 553 |
|
|
2025
Q4 | $83.9M | Buy |
5,893,288
+4,162,433
| +240% | +$40.9M | 0.01% | 1154 |
|
|
2025
Q3 | $13.6M | Buy |
1,730,855
+37,563
| +2% | +$267K | ﹤0.01% | 2965 |
|
|
2025
Q2 | $9.7M | Buy |
1,693,292
+356,421
| +27% | +$2.3M | ﹤0.01% | 3104 |
|
|
2025
Q1 | $10.9M | Buy |
1,336,871
+256,840
| +24% | +$2.38M | ﹤0.01% | 2941 |
|
|
2024
Q4 | $10.2M | Buy |
1,080,031
+516,059
| +92% | +$5.36M | ﹤0.01% | 3025 |
|
|
2024
Q3 | $6.02M | Buy |
563,972
+77,205
| +16% | +$841K | ﹤0.01% | 2878 |
|
|
2024
Q2 | $4.83M | Sell |
486,767
-411,129
| -46% | -$4.22M | ﹤0.01% | 2901 |
|
|
2024
Q1 | $10.6M | Buy |
897,896
+73,188
| +9% | +$936K | ﹤0.01% | 2220 |
|
|
2023
Q4 | $11.7M | Buy |
824,708
+303,038
| +58% | +$3.44M | ﹤0.01% | 1970 |
|
|
2023
Q3 | $6.34M | Buy |
521,670
+121,102
| +30% | +$1.56M | ﹤0.01% | 2354 |
|
|
2023
Q2 | $5.03M | Buy |
400,568
+130,321
| +48% | +$1.55M | ﹤0.01% | 2584 |
|
|
2023
Q1 | $3M | Sell |
270,247
-306,104
| -53% | -$3.77M | ﹤0.01% | 3005 |
|
|
2022
Q4 | $7.04M | Buy |
576,351
+392,760
| +214% | +$4.42M | ﹤0.01% | 2183 |
|
|
2022
Q3 | $1.92M | Sell |
183,591
-96,739
| -35% | -$1.08M | ﹤0.01% | 3194 |
|
|
2022
Q2 | $3.01M | Sell |
280,330
-232,112
| -45% | -$1.91M | ﹤0.01% | 2794 |
|
|
2022
Q1 | $4.85M | Buy |
512,442
+36,572
| +8% | +$343K | ﹤0.01% | 2569 |
|
|
2021
Q4 | $5.5M | Buy |
475,870
+148,024
| +45% | +$1.65M | ﹤0.01% | 2721 |
|
|
2021
Q3 | $3.13M | Buy |
327,846
+184,656
| +129% | +$1.89M | ﹤0.01% | 3164 |
|
|
2021
Q2 | $1.38M | Sell |
143,190
-185,310
| -56% | -$1.81M | ﹤0.01% | 3908 |
|
|
2021
Q1 | $3.25M | Buy |
328,500
+61,602
| +23% | +$954K | ﹤0.01% | 3045 |
|
|
2020
Q4 | $6.16M | Buy |
266,898
+89,438
| +50% | +$1.83M | ﹤0.01% | 2260 |
|
|
2020
Q3 | $2.51M | Sell |
177,460
-5,331
| -3% | -$77.7K | ﹤0.01% | 2844 |
|
|
2020
Q2 | $2.76M | Buy |
182,791
+8,327
| +5% | +$101K | ﹤0.01% | 2575 |
|
|
2020
Q1 | $1.61M | Sell |
174,464
-124,974
| -42% | -$1.19M | ﹤0.01% | 2948 |
|
|
2019
Q4 | $2.92M | Sell |
299,438
-556,404
| -65% | -$5.09M | ﹤0.01% | 3166 |
|
|
2019
Q3 | $6.86M | Buy |
855,842
+561,151
| +190% | +$6.09M | ﹤0.01% | 2087 |
|
|
2019
Q2 | $3.68M | Buy |
294,691
+137,703
| +88% | +$1.75M | ﹤0.01% | 2584 |
|
|
2019
Q1 | $2.13M | Sell |
156,988
-696,041
| -82% | -$8.5M | ﹤0.01% | 2932 |
|
|
2018
Q4 | $8.17M | Buy |
853,029
+579,214
| +212% | +$6.37M | ﹤0.01% | 1734 |
|
|
2018
Q3 | $3.31M | Buy |
273,815
+344
| +0.1% | +$4.81K | ﹤0.01% | 2731 |
|
|
2018
Q2 | $4.27M | Sell |
273,471
-276,268
| -50% | -$4.18M | ﹤0.01% | 2474 |
|
|
2018
Q1 | $8.27M | Buy |
549,739
+316,537
| +136% | +$4.82M | ﹤0.01% | 1863 |
|
|
2017
Q4 | $3.36M | Sell |
233,202
-70,421
| -23% | -$968K | ﹤0.01% | 2733 |
|
|
2017
Q3 | $4.58M | Buy |
303,623
+181,771
| +149% | +$2.4M | ﹤0.01% | 2285 |
|
|
2017
Q2 | $1.23M | Buy |
121,852
+17,461
| +17% | +$140K | ﹤0.01% | 3443 |
|
|
2017
Q1 | $744K | Sell |
104,391
-157,867
| -60% | -$998K | ﹤0.01% | 3754 |
|
|
2016
Q4 | $1.3M | Buy |
262,258
+118,545
| +82% | +$820K | ﹤0.01% | 3325 |
|
|
2016
Q3 | $1.06M | Sell |
143,713
-32,867
| -19% | -$222K | ﹤0.01% | 3378 |
|
|
2016
Q2 | $965K | Buy |
176,580
+88,298
| +100% | +$618K | ﹤0.01% | 3409 |
|
|
2016
Q1 | $746K | Buy |
88,282
+24,655
| +39% | +$175K | ﹤0.01% | 3481 |
|
|
2015
Q4 | $617K | Buy |
63,627
+19,486
| +44% | +$176K | ﹤0.01% | 3784 |
|
|
2015
Q3 | $617K | Buy |
44,141
+13,597
| +45% | +$213K | ﹤0.01% | 3721 |
|
|
2015
Q2 | $432K | Buy |
30,544
+13,144
| +76% | +$158K | ﹤0.01% | 4252 |
|
|
2015
Q1 | $189K | Buy |
17,400
+1,900
| +12% | +$16.7K | ﹤0.01% | 4935 |
|
|
2014
Q4 | $129K | Buy |
+15,500
| New | +$106K | ﹤0.01% | 5450 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
HI
UBS Group's FOLD Position: Q1 2026 in Review
UBS Group increased its Amicus Therapeutics (FOLD) stake by 171% in Q1 2026, buying an estimated $144M and bringing the position to 15,957,913 shares worth $231M. The position accounts for 0.03% of the portfolio, ranked #553.
UBS Group first reported a position in FOLD in Q4 2014 and has held it in 46 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- UBS Group held 15,957,913 shares of Amicus Therapeutics worth $231M as of Q1 2026.
- UBS Group bought 10,064,625 Amicus Therapeutics shares in Q1 2026, an estimated $144M.
- Amicus Therapeutics made up 0.03% of UBS Group's portfolio in Q1 2026, its #553 holding.
- UBS Group first reported a position in Amicus Therapeutics in Q4 2014 and has held it in 46 quarters since.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.